Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Phase 2 Completed 1 enrolled AKARI Therapeutics Radboud University Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.

Timeline

Start: 2016-02
Primary completion: 2018-03-20
Completion: 2018-03-20

Outcome

Met primary endpoint

release “Primary endpoint met in Phase II COBALT clinical trial of Coversin™ for patients with PNH who have never received a complement blocking therapy.” akaritx.com ↗

Publications

Results Schols S, Nunn MA, Mackie I, Weston-Davies W, Nishimura JI, Kanakura Y, Blijlevens N, Muus P, Langemeijer S. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan). Br J Haematol. 2020 Jan;188(2):334-337. doi: 10.1111/bjh.16305. Epub 2019 Dec 16. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Coversin	Protein / enzyme biologic	0.1425 mg/kg	Subcutaneous